Centogene to Open New Lab for COVID-19 Testing

April 16, 2020
BioPharm International Editors

The lab is expected to open in April 2020 and will increase the company’s capacity for diagnostic testing of rare genetic diseases along with its COVID-19 capabilities.

Centogene, a Germany-based commercial-stage company focused on rare diseases, announced on April 15, 2020 that it will open a new laboratory in Hamburg, Germany to increase testing capacity for COVID-19.

The lab facilities and equipment were acquired from Provecs Medical, a company formerly active in cancer immunotherapy, a company press release said. The lab is expected to open in April 2020 and will increase the company’s capacity for diagnostic testing of rare genetic diseases along with its COVID-19 capabilities.

"The opening of our lab in Hamburg will significantly contribute to the scaling and success of our COVID-19 testing initiative,” said Dr. Arndt Rolfs, CEO, Centogene, in the press release. “Once we have overcome the challenges of this pandemic and returned to a sense of normalcy, we will further equip our labs in order to continue to strengthen our commitment to rare disease patients around the world ─ offering transformational medical solutions."

Source: Centogene